1. Most Discussed
  2. Gainers & Losers
UNS 0.5¢

Pharma are still a bunch of tight a#@!s

  1. IndiJo

    2,415 Posts.

    So with Abbvie looking to Unilife, I think its a good time to look at the devices that are being used with the recently approved Novartis drug Cosentyx for psoriasis.

    In trials the IL-17a based drugs easily outclass/perform the older TNF drugs like Humira and Enbrel. Novartis are the first of several to get their their IL-17a drug Cosentyx to market. (Amgen-Astra , Lilly etc close behind)

    The main reason Cosentyx was on my radar is it's 300mg concentration is too large for a single autoinjector or pfs. So IMO this type of drug being thrown into somebodies wearable will show the readiness for pharma to adopt the more expensive devices. If patient convenience is a real driver then why have them use two prefilled syringes or autoinjectors when they can use a wearable?

    LOL, the answer is two PFS with needle guards are about $0.80-1.00 and two Autoinjectors are about $5-6 vs the touted $20-30 for a wearable. Not to mention that current filling lines are geared around filling pfs that go into needle guards or autoinjector/pens....vs needing a machine that will insert the filled cartridge into a wearable and complete the assembly of the wearable. Its a higher capital cost to fill and pack the wearable, something that compounds the additional device cost

    So it appears at this time that Novartis are comfortable with their drug advantage and dont feel the need to go to town on their devices. Abbvie, on the flipside with it's older TNF drug looks to be going the device tech route to stay competitive in the psoriasis space

    So whilst people regularly bash std non safety pfs being inserted into needle shields to make a safety syringe as being rubbish, not worthy of comparison etc compared to our Unifill safety syringe...well here is first cab off the rank for 2015 and Novartis have no problem continuing to use needle shields for a drug that is going to be a big earner for them.

    And like all combination drugs coming through to the market, this drug-device combination underwent human factor studies and was used in trials where patients completed surveys on their ability to use the devices and their satisfaction.

    Pen


    Prefilled

    Device instructions
    http://www.pharma.us.novartis.com/product/pi/pdf/cosentyx_pmg.pdf

    What Novartis do for other indications like arthritis or for life cycle management; or in response to their competitors like Medimmune-Amgen and Brodalumab and also Eli Lilly with Ixekizumab (other IL17 drugs) will continue to be of interest.

    If for nothing else Novartis were doing a lot of studies into wearable injectors several years ago and this trial looked at Cosentyx delivered as a single 300mg dose

    https://clinicaltrials.gov/ct2/show/NCT01539213?term=NCT01539213&rank=1

DISCLAIMER:
Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.

Top

Thank you for visiting HotCopper

We have detected that you are running ad blocking software.


HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.